Morbidity of lupus anticoagulants in children: A single institution experience

Autores
Casais, Patricia; Meschengieser, Susana S.; Gennari, Laura C.; Alberto, Maria Fabiana; Sánchez Luceros, Analía Gabriela; Blanco, Alicia Noemi; Lazzari, María Ángela
Año de publicación
2004
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: The lupus anticoagulant (LA) and the anticardiolipin antibodies (ACA) are the antiphospholipid antibodies more relevant clinically. Their clinical manifestations are diverse with most patients being asymptomatic while others present venous or arterial thrombosis, and more rarely, bleeding. Our objectives were to evaluate clinical presentation of LA in children and to correlate it to LA behavior. Patients and methods: A retrospective cohort of patients (under 18 years old) who had a positive determination of LA followed by at least another determination of LA at a variable period was evaluated. Personal and family history, including infectious diseases temporally related to the event, were recorded. The screening of other coagulation disorders was performed according to symptoms, family history or laboratory results. Results: Thirty-six patients were evaluated, median age was 10.8 years old, and 52.8% were female. Asymptomatic patients were 19.4% (7/36) of study population. Bleeding and thrombosis were found in 52.8% and 27.8%, respectively. Median LA determinations per patient were 3. von Willebrand disease was diagnosed in 66.7% of patients consulting for bleeding. A concomitant hemostatic defect was found in 8/10 patients with thrombosis (p=0.003). LA behavior was not uniform and not correlated to symptoms. Conclusions: Most LA found in children is incidental and asymptomatic. In children with bleeding, LA might be a fortuitous finding associated with VWD. The persistence of LA does not imply a higher risk of thrombosis. © 2004 Elsevier Ltd. All rights reserved.
Fil: Casais, Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Meschengieser, Susana S.. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Gennari, Laura C.. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Sánchez Luceros, Analía Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Blanco, Alicia Noemi. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Materia
Bleeding
Thrombophilia
Thrombosis
Von Willebrand Disease
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/66454
Acceder
id CONICETDig_78ba867c5d7893920fff9886b38fb028
oai_identifier_str oai:ri.conicet.gov.ar:11336/66454
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Morbidity of lupus anticoagulants in children: A single institution experienceCasais, PatriciaMeschengieser, Susana S.Gennari, Laura C.Alberto, Maria FabianaSánchez Luceros, Analía GabrielaBlanco, Alicia NoemiLazzari, María ÁngelaBleedingThrombophiliaThrombosisVon Willebrand Diseasehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: The lupus anticoagulant (LA) and the anticardiolipin antibodies (ACA) are the antiphospholipid antibodies more relevant clinically. Their clinical manifestations are diverse with most patients being asymptomatic while others present venous or arterial thrombosis, and more rarely, bleeding. Our objectives were to evaluate clinical presentation of LA in children and to correlate it to LA behavior. Patients and methods: A retrospective cohort of patients (under 18 years old) who had a positive determination of LA followed by at least another determination of LA at a variable period was evaluated. Personal and family history, including infectious diseases temporally related to the event, were recorded. The screening of other coagulation disorders was performed according to symptoms, family history or laboratory results. Results: Thirty-six patients were evaluated, median age was 10.8 years old, and 52.8% were female. Asymptomatic patients were 19.4% (7/36) of study population. Bleeding and thrombosis were found in 52.8% and 27.8%, respectively. Median LA determinations per patient were 3. von Willebrand disease was diagnosed in 66.7% of patients consulting for bleeding. A concomitant hemostatic defect was found in 8/10 patients with thrombosis (p=0.003). LA behavior was not uniform and not correlated to symptoms. Conclusions: Most LA found in children is incidental and asymptomatic. In children with bleeding, LA might be a fortuitous finding associated with VWD. The persistence of LA does not imply a higher risk of thrombosis. © 2004 Elsevier Ltd. All rights reserved.Fil: Casais, Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Meschengieser, Susana S.. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Gennari, Laura C.. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Sánchez Luceros, Analía Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Blanco, Alicia Noemi. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaPergamon-Elsevier Science Ltd2004-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/66454Casais, Patricia; Meschengieser, Susana S.; Gennari, Laura C.; Alberto, Maria Fabiana; Sánchez Luceros, Analía Gabriela; et al.; Morbidity of lupus anticoagulants in children: A single institution experience; Pergamon-Elsevier Science Ltd; Thrombosis Research; 114; 4; 1-2004; 245-2490049-3848CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.thromres.2004.06.006info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0049384804003159info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:20:34Zoai:ri.conicet.gov.ar:11336/66454instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:20:35.191CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Morbidity of lupus anticoagulants in children: A single institution experience
title Morbidity of lupus anticoagulants in children: A single institution experience
spellingShingle Morbidity of lupus anticoagulants in children: A single institution experience
Casais, Patricia
Bleeding
Thrombophilia
Thrombosis
Von Willebrand Disease
title_short Morbidity of lupus anticoagulants in children: A single institution experience
title_full Morbidity of lupus anticoagulants in children: A single institution experience
title_fullStr Morbidity of lupus anticoagulants in children: A single institution experience
title_full_unstemmed Morbidity of lupus anticoagulants in children: A single institution experience
title_sort Morbidity of lupus anticoagulants in children: A single institution experience
dc.creator.none.fl_str_mv Casais, Patricia
Meschengieser, Susana S.
Gennari, Laura C.
Alberto, Maria Fabiana
Sánchez Luceros, Analía Gabriela
Blanco, Alicia Noemi
Lazzari, María Ángela
author Casais, Patricia
author_facet Casais, Patricia
Meschengieser, Susana S.
Gennari, Laura C.
Alberto, Maria Fabiana
Sánchez Luceros, Analía Gabriela
Blanco, Alicia Noemi
Lazzari, María Ángela
author_role author
author2 Meschengieser, Susana S.
Gennari, Laura C.
Alberto, Maria Fabiana
Sánchez Luceros, Analía Gabriela
Blanco, Alicia Noemi
Lazzari, María Ángela
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Bleeding
Thrombophilia
Thrombosis
Von Willebrand Disease
topic Bleeding
Thrombophilia
Thrombosis
Von Willebrand Disease
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: The lupus anticoagulant (LA) and the anticardiolipin antibodies (ACA) are the antiphospholipid antibodies more relevant clinically. Their clinical manifestations are diverse with most patients being asymptomatic while others present venous or arterial thrombosis, and more rarely, bleeding. Our objectives were to evaluate clinical presentation of LA in children and to correlate it to LA behavior. Patients and methods: A retrospective cohort of patients (under 18 years old) who had a positive determination of LA followed by at least another determination of LA at a variable period was evaluated. Personal and family history, including infectious diseases temporally related to the event, were recorded. The screening of other coagulation disorders was performed according to symptoms, family history or laboratory results. Results: Thirty-six patients were evaluated, median age was 10.8 years old, and 52.8% were female. Asymptomatic patients were 19.4% (7/36) of study population. Bleeding and thrombosis were found in 52.8% and 27.8%, respectively. Median LA determinations per patient were 3. von Willebrand disease was diagnosed in 66.7% of patients consulting for bleeding. A concomitant hemostatic defect was found in 8/10 patients with thrombosis (p=0.003). LA behavior was not uniform and not correlated to symptoms. Conclusions: Most LA found in children is incidental and asymptomatic. In children with bleeding, LA might be a fortuitous finding associated with VWD. The persistence of LA does not imply a higher risk of thrombosis. © 2004 Elsevier Ltd. All rights reserved.
Fil: Casais, Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Meschengieser, Susana S.. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Gennari, Laura C.. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Alberto, Maria Fabiana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Sánchez Luceros, Analía Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Blanco, Alicia Noemi. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Lazzari, María Ángela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
description Introduction: The lupus anticoagulant (LA) and the anticardiolipin antibodies (ACA) are the antiphospholipid antibodies more relevant clinically. Their clinical manifestations are diverse with most patients being asymptomatic while others present venous or arterial thrombosis, and more rarely, bleeding. Our objectives were to evaluate clinical presentation of LA in children and to correlate it to LA behavior. Patients and methods: A retrospective cohort of patients (under 18 years old) who had a positive determination of LA followed by at least another determination of LA at a variable period was evaluated. Personal and family history, including infectious diseases temporally related to the event, were recorded. The screening of other coagulation disorders was performed according to symptoms, family history or laboratory results. Results: Thirty-six patients were evaluated, median age was 10.8 years old, and 52.8% were female. Asymptomatic patients were 19.4% (7/36) of study population. Bleeding and thrombosis were found in 52.8% and 27.8%, respectively. Median LA determinations per patient were 3. von Willebrand disease was diagnosed in 66.7% of patients consulting for bleeding. A concomitant hemostatic defect was found in 8/10 patients with thrombosis (p=0.003). LA behavior was not uniform and not correlated to symptoms. Conclusions: Most LA found in children is incidental and asymptomatic. In children with bleeding, LA might be a fortuitous finding associated with VWD. The persistence of LA does not imply a higher risk of thrombosis. © 2004 Elsevier Ltd. All rights reserved.
publishDate 2004
dc.date.none.fl_str_mv 2004-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/66454
Casais, Patricia; Meschengieser, Susana S.; Gennari, Laura C.; Alberto, Maria Fabiana; Sánchez Luceros, Analía Gabriela; et al.; Morbidity of lupus anticoagulants in children: A single institution experience; Pergamon-Elsevier Science Ltd; Thrombosis Research; 114; 4; 1-2004; 245-249
0049-3848
CONICET Digital
CONICET
url http://hdl.handle.net/11336/66454
identifier_str_mv Casais, Patricia; Meschengieser, Susana S.; Gennari, Laura C.; Alberto, Maria Fabiana; Sánchez Luceros, Analía Gabriela; et al.; Morbidity of lupus anticoagulants in children: A single institution experience; Pergamon-Elsevier Science Ltd; Thrombosis Research; 114; 4; 1-2004; 245-249
0049-3848
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.thromres.2004.06.006
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0049384804003159
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614188071124992
score 13.070432

Publicaciones similares